Market Scenario:
Although breast cancer is common in
women, even men suffer from the same. Men also have breast tissues and cancer
starts when these tissues start to grow out of control. The breast ducts and
glands present in men are not functional, but cancer in these areas can spread
when cancer cells enter the blood or lymph system and are carried in the whole
body. Men who have suffered from cancer before and undergone radiation therapy
are at a high risk of suffering from male breast cancer.
The rising geriatric population and an
increasingly obese population resulting in high levels of estrogen in males are
expected to drive the growth of the market during the forecast period.
According to an article published by the National Cancer Institute in April
2018, most of the men who suffer from breast cancer are 60 to 70 years old.
Additionally, the rising healthcare expenditure is likely to boost the market
growth. On the other hand, lack of knowledge of the disease and high cost of
treatment may hinder the growth of the market during the forecast period.
The global male
breast cancer treatment market is expected to grow slowly at a CAGR of
~ 3.6% during the forecast period from 2018 to 2023. Male breast cancer is
caused when the breast tissues of males start growing out of control and become
cancerous.
Numerous factors such as increasing obese
population and growing geriatric population are expected to drive the growth of
the market. For instance, in July 2017, the Bristol-Myers Squibb Company
announced a broad clinical collaboration with Clovis Oncology for evaluating
the combination of cancer drugs Nivolumab and Rucaparib in Phase 2 and Phase 3
clinical trials in multiple tumor types.
Moreover, favorable healthcare
expenditures boost the growth of the market. However, lack of knowledge and the
high cost of treatments may hamper the market growth during the assessment
period.
Key players
Achieve Life Sciences, Inc., Pfizer, Eli
Lilly and Company, Bristol-Myers Squibb Company, F. Hoffmann-La Roche, Sanofi,
Novartis AG, BioNumerik Pharmaceuticals Inc., Seattle Genetics, Inc.,
GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical
Industries Ltd., AstraZeneca, Accord Healthcare, and Bayer AG are some of the
key players in the global male breast cancer market.
Segmentation
The global male breast cancer market has
been segmented into type, diagnosis, and treatment.
The market, on the basis of type, has
been segmented into, ductal carcinoma in situ, Paget’s disease of the nipple,
inflammatory breast cancer, and infiltrating ductal carcinoma.
The market, by diagnosis, has been
segmented into, mammography, biopsy, PET scan, CT scan, MRI scan, and other
tests. On the basis of diagnosis, biopsy is anticipated to record the largest
growth owing to its accuracy of diagnosing the disease. It is also expected to
be the fastest growing segment.
By diagnosis, biopsy is further segmented
into, fine needle aspiration biopsy, core biopsy, and excisional biopsy.
The market, by
treatment, has been segmented into, local treatments and systemic treatments.
By treatment, local treatments are
further segment into, surgery and radiation therapy.
Surgery is further segmented into,
mastectomy, breast-conserving surgery, and lymph nodes biopsy.
By treatment, systemic treatments are
further segmented into, chemotherapy, hormone therapy, and targeted therapy.
Hormone therapy is further segmented
into, using drugs and orchiectomy (castration).
Chemotherapy is further segmented into,
adjuvant therapy and neoadjuvant therapy.
Targeted therapy is further segmented
into, for HER2 positive breast cancer, for hormone receptor-positive breast
cancer, and for cancer with BRCA mutations.
The European male breast cancer market
has been segmented into Western Europe and Eastern Europe. Western Europe has
further been classified as Germany, France, the UK, Italy, Spain, and the rest
of Western Europe.
The male breast cancer market in
Asia-Pacific has been segmented into Japan, China, India, South Korea,
Australia, and the rest of Asia-Pacific. The male breast cancer market in the
Middle East and Africa has been segmented into the Middle East and Africa.
The market has been segmented, by region,
into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The
male breast cancer market in the Americas has further been segmented into North
America and South America, with the North American market divided into the US
and Canada.
Regional Market Summary
Geographically, the Americas is
anticipated to dominate the global male breast cancer market owing to the
changing lifestyle and rising prevalence of breast cancer. According to an
article published by, the American Cancer Society in April 2018, the lifetime
risk of getting breast cancer in men is approximately 1 in 833. Europe is
expected to hold the second largest position in the global male breast cancer
market. The market growth in this region is attributed to the growing
prevalence of rare cancers, the availability of funds for research, and
increasing healthcare expenditure. According to the Cancer Research UK, 371 new
cases of male breast cancer were reported in 2015 in the UK.
Asia-Pacific is anticipated to be the
fastest growing region in the market due to the rising awareness regarding
early symptoms of cancer and government support for healthcare facilities. According
to a study published by the European Society for Medical Oncology in January
2016, there were 4.3 million new cases of cancer in China in 2015.
On the other hand, the Middle East and
Africa has the least share of the market. Majority of the market of this region
is expected to be held by the Middle Eastern region due to growing government
initiatives for the healthcare sector.
Browse More Report Details @ https://www.marketresearchfuture.com/reports/male-breast-cancer-market-6505
No comments:
Post a Comment